Jionoside A1
(Synonyms: 焦地黄苯乙醇苷A1) 目录号 : GC36369
Jionoside A1 分离于 Radix Rehmanniae Praeparata 中，具有剂量依赖性免疫增强活性并对 H2O2 处理的 SH-SY5Y 细胞具有中等保护活性。
Cas No.:120444-60-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Jionoside A1 isolated from Radix Rehmanniae Praeparata displays dose dependent immune-enhancement activity and possesses moderate protective activities on H2O2-treated SH-SY5Y cells[1].
[1]. Shen L, et al. Identification of bioactive ingredients with immuno-enhancement and anti-oxidative effects from Fufang-Ejiao-Syrup by LC-MS(n) combined with bioassays. J Pharm Biomed Anal. 2016 Jan 5;117:363-71.
| Cas No. | 120444-60-2 | SDF | |
| 别名 | 焦地黄苯乙醇苷A1 | ||
| Canonical SMILES | COC1=C(O)C=CC(/C=C/C(O[C@H]2[C@@H]([C@H]([C@H](OCCC3=CC(O)=C(O)C=C3)O[C@@H]2CO[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)CO)O)O[C@@]5([H])[C@@H]([C@@H]([C@@H](O)[C@H](C)O5)O)O)=O)=C1 | ||
| 分子式 | C36H48O20 | 分子量 | 800.75 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2488 mL | 6.2441 mL | 12.4883 mL |
| 5 mM | 0.2498 mL | 1.2488 mL | 2.4977 mL |
| 10 mM | 0.1249 mL | 0.6244 mL | 1.2488 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Iridoid glycosides link with phenylpropanoids from Rehmannia glutinosa
Nat Prod Res 2022 Oct;36(20):5370-5375.PMID:34039230DOI:10.1080/14786419.2021.1931189.
Two new iridoid glycosides link with phenylpropanoids, rehmanniosides G (1) and H (2) along with 11 known compounds, 6-O-(E)-caffeoylajugol (3), 6-O-(E)-feruloylajugol (4), verbasoside (5), jionoside C (6), acteoside (7), leucosceptoside A (8), brachynoside (9), jionoside B1 (10), Jionoside A1 (11), isoacteoside (12) and isomartynoside (13) were isolated from the roots of Rehmannia glutinosa (Gaertn.) DC. Their chemical structures were elucidated on the basis of extensive spectroscopic methods, including 1D, 2D NMR and mass spectra. Compounds 7 - 11 showed significant inhibitory α-glucosidase with IC50 values ranging from 261.4 to 408.7 μM (acarbose, IC50 of 204.2 ± 19.9 μM).[Formula: see text].
[Chemical constituents from Rehmannia glutinosa]
Zhongguo Zhong Yao Za Zhi 2011 Nov;36(22):3125-9.PMID:22375391doi
Objective: To study the chemical constituents from the roots of Rehmannia glutinosa. Method: The compounds were isolated by various chromatographic methods and identified by spectroscopic analysis. Result: Twelve compounds were isolated and their structures were identified as 5-hydroxymethyl-pyrrole-2-carbaldehyde (1), 5-hydroxymethyl furfural (2), tyrosol (3), 5,6-dihydroxy-beta-ionone (4), 6-O-E-feruloyl ajugol (5), acteoside (6), leucosceptoside A (7), martynoside (8), isomartynoside (9), purpureaside C (10), Jionoside A1 (11), and jionoside B1 (12). Conclusion: Compounds 1, 3 and 9 were isolated from the genus Rehmannia for the first time.
Identification of bioactive ingredients with immuno-enhancement and anti-oxidative effects from Fufang-Ejiao-Syrup by LC-MS(n) combined with bioassays
J Pharm Biomed Anal 2016 Jan 5;117:363-71.PMID:26433168DOI:10.1016/j.jpba.2015.09.024.
Fufang Ejiao Syrup (FES) is a widely used immune-boosting Traditional Chinese Medicine (TCM) in Eastern Asian countries. This study attempts to investigate the bioactive compounds in FES. First, FES extract was separated into fractions to facilitate the investigation and 72 compounds were identified using LC-MS(n). Subsequently, Immune-enhancement effects of FES and its components were investigated on bone marrow cells and neuroprotective effects against H2O2 induced oxidative damage were evaluated in SH-SY5Y neuroblastoma cells and bEnd.3. Our results indicated that fraction 3, 5, 6 and 8 showed significant improvements on immune function, while several fractions had cytoprotective effects against H2O2-induced oxidative injury. Jionoside A1 isolated from Radix Rehmanniae Praeparata displayed dose dependent immune-enhancement activity. 20(R)-ginsenoside Rg3 could protect bEnd.3 against oxidative damage. Furthermore, echinacoside, Jionoside A1, vitexin-2-O-rhamnoside, acteoside and isoacteoside possessed moderate protective activities on H2O2-treated SH-SY5Y cells. In conclusion, our study provided both chemical and biological evidences to support clinical application of FES.
Rehmanniae Radix Preparata suppresses bone loss and increases bone strength through interfering with canonical Wnt/β-catenin signaling pathway in OVX rats
Osteoporos Int 2019 Feb;30(2):491-505.PMID:30151623DOI:10.1007/s00198-018-4670-y.
Rehmanniae Radix Preparata (RRP) improves bone quality in OVX rats through the regulation of bone homeostasis via increasing osteoblastogenesis and decreasing osteoclastogenesis, suggesting it has a potential for the development of new anti-osteoporotic drugs. Introduction: Determine the anti-osteoporotic effect of RRP in ovariectomized (OVX) rats and identify the signaling pathway involved in this process. Methods: OVX rats were treated with RRP aqueous extract for 14 weeks. The serum levels of tartrate-resistant acid phosphatase (TRAP), receptor activator of nuclear factor kappa-Β ligand (RANKL), alkaline phosphatase (ALP), and osteoprotegerin (OPG) were determined by ELISA. Bone histopathological alterations were evaluated by H&E, Alizarin red S, and Safranin O staining. Bone mineral density (BMD) and bone microstructure in rat femurs and lumbar bones were determined by dual-energy X-ray absorptiometry and micro-computed tomography. Femoral bone strength was detected by a three-point bending assay. The expression of Phospho-glycogen synthase kinase 3 beta (p-GSK-3β), GSK-3β, Dickkopf-related protein 1 (DKK1), cathepsin K, OPG, RANKL, IGF-1, Runx2, β-catenin, and p-β-catenin was determined by western blot and/or immunohistochemical staining. Results: Treatment of OVX rats with RRP aqueous extract rebuilt bone homeostasis demonstrated by increasing the levels of OPG as well as decreasing the levels of TRAP, RANKL, and ALP in serum. Furthermore, RRP treatment preserved BMD and mechanical strength by increasing cortical bone thickness and epiphyseal thickness as well as improving trabecular distribution in the femurs of OVX rats. In addition, RRP downregulated the expression of DKK1, sclerostin, RANKL, cathepsin K, and the ratio of p-β-catenin to β-catenin, along with upregulating the expression of IGF-1, β-catenin, and Runx2 and the ratio of p-GSK-3β to GSK-3β in the tibias and femurs of OVX rats. Echinacoside, Jionoside A1/A2, acetoside, isoacetoside, jionoside B1, and jionoside B2 were identified in the RRP aqueous extract. Conclusion: RRP attenuates bone loss and improves bone quality in OVX rats partly through its regulation of the canonical Wnt/β-catenin signaling pathway, suggesting that RRP has the potential to provide a new source of anti-osteoporotic drugs.